1-5 of 5
Dean A. Fennell
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ganetespib in Combination with Pemetrexed–Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial

Dean A. Fennell, Sarah Danson, Penella J. Woll, Martin Forster, Denis Talbot, Jennifer Child, Laura Farrelly, Annabel Sharkey, Sara Busacca, Yenting Ngai, Allan Hackshaw, Graham M. Wheeler
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18): 4748–4755.
https://doi.org/10.1158/1078-0432.CCR-20-1306
Published: 15 September 2020
View article titled, Ganetespib in Combination with Pemetrexed–Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial
Open the PDF for Ganetespib in Combination with Pemetrexed–Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial in another window
Includes: Supplementary data
Journal Articles

Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways

Hiu-Fung Yuen, Ka-Kui Chan, Claire Grills, James T. Murray, Angela Platt-Higgins, Osama Sharaf Eldin, Ken O'Byrne, Pasi Janne, Dean A. Fennell, Patrick G. Johnston, Philip S. Rudland, Mohamed El-Tanani
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (2): 380–391.
https://doi.org/10.1158/1078-0432.CCR-11-2035
Published: 16 January 2012
View article titled, Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
Open the PDF for Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways in another window
Includes: Supplementary data
Journal Articles

Bortezomib Inhibits Nuclear Factor-κB–Dependent Survival and Has Potent In vivo Activity in Mesothelioma

Andrea Sartore-Bianchi, Fabio Gasparri, Arturo Galvani, Linda Nici, James W. Darnowski, Dario Barbone, Dean A. Fennell, Giovanni Gaudino, Camillo Porta, Luciano Mutti
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19): 5942–5951.
https://doi.org/10.1158/1078-0432.CCR-07-0536
Published: 01 October 2007
View article titled, Bortezomib Inhibits Nuclear Factor-κB–Dependent Survival and Has Potent <em>In vivo</em> Activity in Mesothelioma
Open the PDF for Bortezomib Inhibits Nuclear Factor-κB–Dependent Survival and Has Potent <em>In vivo</em> Activity in Mesothelioma in another window
Journal Articles

In vivo Loss of Expression of Argininosuccinate Synthetase in Malignant Pleural Mesothelioma Is a Biomarker for Susceptibility to Arginine Depletion

Peter W. Szlosarek, Astero Klabatsa, Arben Pallaska, Michael Sheaff, Paul Smith, Tim Crook, Matthew J. Grimshaw, Jeremy P. Steele, Robin M. Rudd, Frances R. Balkwill, Dean A. Fennell
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (23): 7126–7131.
https://doi.org/10.1158/1078-0432.CCR-06-1101
Published: 04 December 2006
View article titled, <em>In vivo</em> Loss of Expression of Argininosuccinate Synthetase in Malignant Pleural Mesothelioma Is a Biomarker for Susceptibility to Arginine Depletion
Open the PDF for <em>In vivo</em> Loss of Expression of Argininosuccinate Synthetase in Malignant Pleural Mesothelioma Is a Biomarker for Susceptibility to Arginine Depletion in another window
Journal Articles

Caspase Regulation in Non–Small Cell Lung Cancer and its Potential for Therapeutic Exploitation

Dean A. Fennell
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (6): 2097–2105.
https://doi.org/10.1158/1078-0432.CCR-04-1482
Published: 23 March 2005
View article titled, Caspase Regulation in Non–Small Cell Lung Cancer and its Potential for Therapeutic Exploitation
Open the PDF for Caspase Regulation in Non–Small Cell Lung Cancer and its Potential for Therapeutic Exploitation in another window